Skip to main content

Table 2 Baseline characteristics (mean ± SD) of the TEMPO 3:4 study cohort [12, 24, 39]

From: A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model

Characteristic

Placebo arm

(N = 484)

Treatment arm

(N = 961)

Overall

(N = 1445)

Male, no. (%)

251 (51.9)

495 (51.5)

746 (51.6)

Age (years)

39 ± 7

39 ± 7

38.7 ± 7.1

TKV (mL)

1668 ± 873

1705 ± 921

1692 ± 905

eGFR (mL/min/1.73 m2)a

82.14 ± 22.73

81.35 ± 21.02

81.61 ± 21.60

  1. CKD chronic kidney disease, eGFR estimated glomerular filtration rate, TKV total kidney volume
  2. aBaseline eGFR was based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) equation [15], used to ascertain CKD stage at baseline
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us